These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 741439)

  • 41. Defibrinogenating enzymes.
    Bell WR
    Drugs; 1997; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acquired coagulation inhibitor delaying fibrinopeptide release.
    Marciniak E; Greenwood MF
    Blood; 1979 Jan; 53(1):81-92. PubMed ID: 758215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human platelet fibrinogen: a protein different from plasma fibrinogen.
    Soria J; Soria C; Samama M; Poirot E; Kling C
    Pathol Biol (Paris); 1976 Dec; 24 Suppl():15-7. PubMed ID: 796805
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The activation of plasma factor XIII with the snake venom enzymes ancrod and batroxobin marajoensis.
    Walter M; Nyman D; Krajnc V; Duckert F
    Thromb Haemost; 1977 Aug; 38(2):438-46. PubMed ID: 579487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His).
    Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M
    Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of reptilase and thrombin-induced changes in fibrinogen subunits by isoelectric focussing.
    Exner T; Rickard KA; Kronenberg H
    Thromb Res; 1983 Aug; 31(3):489-97. PubMed ID: 20218004
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
    Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
    Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.
    Borrell M; Vila L; Solá J; Coll I; Fontcuberta J
    Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fibrinogen Vicenza and Genova II: two new cases of congenital dysfibrinogenemia with isolated defect of fibrin monomer polymerization and inhibitory activity on normal coagulation.
    Rodeghiero F; Castaman GC; Dal Belin Peruffo A; Dini E; Galletti A; Barone E; Gastaldi G
    Thromb Haemost; 1987 Jun; 57(3):252-8. PubMed ID: 2958952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human fibrinogen heterogeneities: determination of the major Aalpha chain derivatives in blood.
    Galanakis DK; Mosesson MW
    Thromb Res; 1983 Aug; 31(3):403-13. PubMed ID: 20217997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A new case of dysfibrinogenemia].
    Krause W; Heene D; Lasch HG
    Klin Wochenschr; 1971 Jul; 49(14):806-8. PubMed ID: 5563018
    [No Abstract]   [Full Text] [Related]  

  • 52. An abnormal fibrinogen with delayed fibrinopeptide A release.
    Lane DA; VanRoss M; Kakkar VV; Bottomley KJ; Dhir K; Holt LP; MacIver JE
    Br J Haematol; 1980 Sep; 46(1):89-98. PubMed ID: 7426452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
    Soya K; Terasawa F; Okumura N
    Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Dysfibrinogenemia. A new case: dysfibrinogenemia Giessen III (author's transl)].
    Matthias FR; Krause WH; Ganssert S; Mueller K; Lasch HG
    Klin Wochenschr; 1977 Jun; 55(11):539-43. PubMed ID: 881774
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fibrinogen and dysfibrinogenemia.
    Morse EE
    Ann Clin Lab Sci; 1980; 10(4):351-5. PubMed ID: 7447388
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SDS polyacrylamide gel characterization of serum FDP produced in response to ancrod and streptokinase/plasminogen infusion in man.
    Lane DA; Robbins A; Rampling MW; Kakkar VV
    Br J Haematol; 1977 May; 36(1):137-48. PubMed ID: 871418
    [No Abstract]   [Full Text] [Related]  

  • 57. Fibrinogen Seattle II: defective release of fibrinopeptide A in a slow clotting fibrinogen.
    Schreiber WE; Schmer G
    Thromb Res; 1985 Jan; 37(1):45-52. PubMed ID: 3983901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A two-step fibrinogen--fibrin transition in blood coagulation.
    Blombäck B; Hessel B; Hogg D; Therkildsen L
    Nature; 1978 Oct; 275(5680):501-5. PubMed ID: 692730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fibrinogen Bergamo I (A alpha 16Arg----Cys): susceptibility towards thrombin following aminoethylation, methylation or carboxamidomethylation of cysteine residues.
    Reber P; Furlan M; Beck EA; Finazzi G; Buelli M; Barbui T
    Thromb Haemost; 1985 Aug; 54(2):390-3. PubMed ID: 4082078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of thrombosis by sequential therapy with ancrod followed by streptokinase. Clinical pharmacology and rheology.
    Forbes CD; Barbenell J; Prentice CR
    Haemostasis; 1976; 5(6):348-54. PubMed ID: 1017726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.